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(57) ABSTRACT 
Described herein are particular embodiments relating to a 
microfluidic device that may be utilized for cell sensing, 
counting, and/or sorting. Particular aspects relate to a micro-
fabricated device that is capable of differentiating single cell 
types from dense cell populations. One particular embodi-
ment relates a device and methods of using the same for 
sensing, counting, and/or sorting leukocytes from whole, 
undiluted blood samples. 
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MICROFLUIDIC DEVICE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of priority under 35 
U.S.C. §120 as a continuation of U.S. patent application Ser. 
No. 14/296,199, filed Jun. 4, 2014, now U.S. Pat. No. 9,029, 
158 issued on May 12, 2015, which is a divisional of U.S. 
patent application Ser. No. 12/062,808, filed Apr. 4, 2008, 
now abandoned. This application also includes a claim of 
priority under 35 U.S.C. §119(e) to U.S. provisional patent 
application No. 60/922,296, filedApr. 6, 2007, the entirety of 
which is hereby incorporated by reference. 
STATEMENT OF GOVERNMENT INTEREST 
This work was supported in part by the National Space 
Biomedical Research Institute through NASA, grant number 
NCC 9-58-317. The United States government has certain 
rights in this invention. 
FIELD OF THE INVENTION 
The present disclosure relates to fabricated microfluidic 
devices that can be utilized as cell sensors and/or actuators. In 
certain embodiments, the microfluidic device may be used for 
labeling, sensing, differentiating, and/or sorting targets, par-
ticularly cell populations. 
BACKGROUND OF THE INVENTION 
Standard cell sensors or actuators are generally based on 
flow cytometry and employ one or a combination of electrical 
impedance sensing, light scattering measurement, and chemi-
cal or immunostaining followed by optical sensing. 
For differentiation of blood cells by electrical impedance 
sensing, red blood cells are removed by lysing in order to 
reduce the blood volume. Lysing is generally done through 
the use of saponin or surfactants. During the lysing process, 
the leukocyte cell volume changes depending on cell type, 
due to the leakage of cytoplasm contents and cell nucleus 
shrinkage in varying amounts. Fujimoto, Sysmex J. Int. 9 
(1999). Thus, normally 2-part (lymphocytes versus granulo-
cytes) or even 3-part (lymphocytes, neutrophils, and other 
leukocytes) differential can be achieved by simple electrical 
impedance measurement of particle volume. Hughes-Jones, 
et al., J. Clin. Pathol. 27; 623-625 (1974); Oberjat, et al., J. 
Lab. Clin. Med. 76; 518 (1970); Vandilla, et al., Proc. Soc. 
Exp. Biol. Med. 125; 367 (1967); Maeda, et al., Clin. Pathol. 
27; 1117-1200 (1979); Maeda, et al., Clin. Pathol. 9; 555-558 
(1982). Combining direct current and alternating current 
impedance, special acidic hemolysis in basophile channel 
and alkali hemolysis in eosinophil channel, a 5-part leukocyte 
differential can be achieved. Tatsumi, et al., Sysmex J. Int. 9; 
9 -20 (1999). 
Alternative optical methods are based on light scattering 
and fluorescence staining of organelles, granules, and nuclei. 
Generally, low-angle scattered light contains information on 
cell size and high-angle scattered light can be used to probe 
internal composition of the cell. To achieve 5-part differen-
tial, certain leukocyte populations, such as eosinophils, 
require special stain to change its scattering characteristics 
from other granulocytes, and basophils typically need to be 
counted separately following the differential lysis of other 
leukocytes. McKenzie, Clinical Laboratory Hematology, 
Prentice Hall, 2004; Fujimoto, Sysmex J. Int. 9 (1999). 
2 
In general, conventional automated cell analyzers are 
bulky, expensive, and mechanically complex, which restricts 
their locations to hospitals or central laboratories. Conven-
tional cell analyzers require larger sample volumes and gen- 
t erate more waste than the systems developed using microde-
vices. Furthermore, for analysis of certain cell types, such as 
leukocytes, accuracy and speed of counting, differentiation, 
and/or sorting is important for determining disease state and 
treatment. 
10 
BRIEF DESCRIPTION OF THE SEVERAL 
VIEWS OF THE DRAWING(S) 
FIG. 1A shows the molecular structure of acridine orange. 
i5 	 FIG. 1B shows leukocyte staining results with acridine 
orange. 
FIG. 2 shows the top view of one embodiment of a novel 
fabricated microfluidic apparatus. 
20 	 FIG. 3 shows one embodiment of the optical system setup. 
FIG. 4A shows erythrocyte concentration in whole blood. 
FIG. 4B shows leukocyte staining in whole blood with 
acridine orange at a concentration of 100 ng/mL. 
FIG. 4C shows leukocyte staining in whole blood with 
25 acridine orange at a concentration of 1 µg/mL. 
FIG. 4D shows leukocyte staining in whole blood with 
acridine orange at a concentration of 10 µg/mL. 
FIG. 4E shows leukocyte staining in whole blood with 
acridine orange at a concentration of 100 µg/mL. 
30 	 FIG. 4F shows leukocyte staining in whole blood with 
acridine orange at a concentration of 1 mg/mL. 
FIG. 5 shows fluorescent signal bleaching from a single 
leukocyte in one embodiment. 
FIG. 6A shows an image of background and a 5 M bead 
35 with focused laser illumination flow taken by CCD camera 
with long pass emission filter, according to one embodiment. 
FIG. 6B shows an image of background and a 5 µm bead 
with laser illumination flow taken by CCD camera with long 
pass emission filter, according to one embodiment. 
40 FIG. 6C shows an image of background and a 5 µm bead 
with diffused laser illumination flow taken by CCD camera 
with long pass emission filter, according to one embodiment. 
FIG. 6D shows an image of background and the trace of a 
5 µm bead with diffused laser illumination flow taken by CCD 
45 camera with long pass emission filter, according to one 
embodiment. 
FIG. 7 shows a graph of detection of 5 µm fluorescent beads 
detection with photodiode detector with long pass emission 
filter. 
50 FIG. 8A shows background image of focused laser beam 
from video taken by CCD camera with long pass emission 
filter, according to one embodiment. 
FIG. 8B shows a signal from a leukocyte from diluted 
whole blood testing from video taken by CCD camera with 
55 long pass emission filter, according to one embodiment. 
FIG. 9 shows the time trace of amplified photodiode signal 
of acridine orange stained undiluted whole blood with green 
emission filter centered at 525 mu, and peaks labeled, accord-
ing to one embodiment. 
60 	 FIG. 10 shows a histogram of signal intensity from photo- 
diode detector with green emission filter centered at 525 mu. 
FIG. 11 shows a histogram of signal intensity from photo-
diode detector with red emission filter centered at 650 mu. 
FIG. 12A shows an illustration of a handheld detection box 
65 instrument according to one embodiment. 
FIG. 12B shows an assembled detection box instrument 
according to one embodiment. 
US 9,234,884 B2 
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FIG. 13A shows the top view of an apparatus according to 
one particular embodiment. 
FIG. 13B shows the top view of an apparatus according to 
one particular embodiment. 
SUMMARY OF THE INVENTION 
Certain embodiments disclosed herein include a microflu-
idic apparatus comprising a substrate having a first channel 
having a definedphysical feature, wherein said first channel is io 
in fluid communication with at least one inlet for receiving a 
fluid, wherein said first channel leads to a restrictive access, 
and wherein said first channel is in fluid communication with 
a second channel having a defined physical feature, wherein 
said second channel is in fluid communication with at least 15 
one fluid flow outlet; and a fluid biological sample. In certain 
embodiments, said defined physical feature is a depression or 
protrusion. In particular embodiments, said fluid biological 
sample comprises blood. In certain embodiments, the microf-
luidic apparatus further comprises a detection zone, and/or a 20 
filter array, each in fluid communication with said channel 
and said fluid flow outlet. 
A microfluidic apparatus comprising a substrate having at 
least one first channel having a defined physical feature; at 
least one first inlet formed in said first channel for receiving a 25 
first fluid; wherein said first channel is in fluid communica-
tion with a bifurcated channel, wherein said bifurcated chan-
nel is in fluid communication with a third channel detection 
zone; at least one second inlet for receiving a second fluid, 
wherein said second inlet is in fluid communication with a 30 
branched channel; a filter structure in fluid communication 
with a reservoir, wherein said reservoir is in fluid communi-
cation with said third channel detection zone; at least one fluid 
flow outlet formed in said third channel; and a fluid sample; 
wherein the ratio of the cross-sectional area of said second 35 
channel compared to the cross-sectional area of said first 
channel is 1:10. In certain embodiments, the defined physical 
feature is a depression or a protrusion. 
In certain embodiments, said filter structure comprises a 
filter array, said first fluid comprises sheath fluid and said 40 
second fluid comprises blood. 
Certain embodiments disclosed herein relate to a detection 
system comprising a microfluidic apparatus and further com-
prising a light source; a lens assembly; a filter assembly; and 
an image capture device. In some embodiments, the detection 45 
system further comprises at least one display unit or at least 
one recording unit. In certain particular embodiments, said 
excitation source comprises a laser, particularly an argon 
laser. In particular embodiments, said filter assembly com-
prises an excitation filter, and at least one emission filter. In 50 
certain embodiments, said filter assembly further comprises 
at least one aperture and at least one neutral density filter. In 
particular embodiments, said filter assembly further com-
prises at least one glass polarizer. 
In certain embodiments, the lens assembly of the detection 55 
system comprises at least one condenser lens, at least one 
objective lens, and at least one beamsplitter. In particular 
embodiments, said image capture device comprises at least 
one CCD camera, CMOS device, photodiode, or photomul-
tiplier tube. In certain embodiments, said filter assembly 60 
comprises at least two emission filters and said image capture 
device comprises at least one photomultiplier tube. In certain 
embodiments, said display unit comprises a computer and 
said recording unit comprises an oscilloscope. In particular 
embodiments, said excitation source comprises an argon 65 
laser; said lens assembly comprises a condenser lens, an 
objective lens, and a beamsplitter; said filter assembly com- 
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prises an excitation filter, a pinhole aperture and a neutral 
density filter, and at least one emission filter; said image 
capture device comprises a CCD camera and a photodiode, 
and said display unit comprises a personal computer, and 
further comprising an amplifier. 
In particular embodiments, said excitation source of the 
detection system comprises an argon laser; said lens assem-
bly comprises a condenser lens, an objective lens, and a 
beamsplitter, said filter assembly comprises an excitation fil-
ter, at least one emission filter; said image capture device 
comprises a photomultiplier tube, and said display unit com-
prises a personal computer. 
Other embodiments disclosed herein relate to a method for 
identifying a target comprising providing a fluid sample to at 
least one microfluidic apparatus, wherein said fluid sample 
contains at least one dye; providing an excitation source to 
induce at least one fluorescent signal in a target; detecting the 
fluorescent signal using a sensor in the apparatus; and iden-
tifying the target based in part on the analysis of the fluores-
cent signal. In certain embodiments, said target is selected 
from the group consisting of: cells, organelles, nuclei, gran-
ules, DNA, and RNA. In other embodiments, said target 
comprises a cell selected from the group consisting of a 
monocyte, a granulocyte, a macrophage, a neutrophil, an 
eosinophil, abasophil, or other leukocyte. In specific embodi-
ments, said target comprises a leukocyte and said dye com-
prises acridine orange. Particular embodiments of the method 
further comprising counting or sorting the target in the sample 
by analysis of the fluorescent signal. In certain embodiments, 
said fluid sample comprises blood. 
DETAILED DESCRIPTION OF THE INVENTION 
The present disclosure relates to fabricated microfluidic 
devices that can be utilized as cell sensors and/or actuators. In 
certain embodiments, the microfluidic device may be used for 
labeling, sensing, differentiating, and/or sorting cell popula-
tions. 
Microfluidic cell sensors and actuators can provide cell 
sensing and counting for a more accurate outcome and a 
lower cost. Particle counting (including bead, erythrocyte, 
and cultured cell) has been demonstrated, for example, by 
electrical impedance sensing, light scattering detection, and 
fluorescent sensing. Gawad, et al. Lab Chip 1; 78 (2001); Lee, 
et al. Proceedings of the 18 th IEEE International Conference 
on Micro Electro Mechanical Systems (MEMS) 678-681 
(2005); Satake et al. Sens. Actuators B: Chem. 83; 77 (2002); 
Morgan, et al. Curr. Appl. Phys. 6, 367-370 (2006); Lee et al., 
J. Micromech. Microeng. 15; 447-454 (2005); Altendorf, et 
al. Proceedings of the International Conference on Solid 
State Sensors and Actuators (Transducers '97) v. 1, p. 531, 
Chicago, Ill. (1997); Holmes et al., Biosens. Bioelectron. 21; 
1621-1630 (2006); Yang et al., Meas. Sci. Technol. 17; 2001-
2009 (2006); Simonnet et al., Anal. Chem. 78; 5653-5663 
(2006); Niehren, et al., Anal. Chem. 67; 2666-2671 (1995). 
In the area of optical sensing, microfabrication has allowed 
development of microdevices to replace glass capillary-based 
flow chambers, and to integrate compact optics and provide 
on-chip sample transport. 
Cell sensing and counting, particularly of leukocytes, is 
cumbersome due in part to the cell population numbers. For 
leukocyte differential in microdevices based on optical sens-
ing, a V-groove microchannel was fabricated by anisotropic 
wet etching of a silicon substrate and 3 -part leukocyte differ-
ential was demonstrated for diluted blood without sheath flow 
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by two-parameter light scattering. Altendorf, Proceedings of 	 studying the red fluorescent signal of an Acridine orange 
the Int'l Conference on Solid State Sensors and Actuators, v. 	 stained diluted blood sample, whereas a 5-part differential 
1, p. 531 (1997). 	 leukocytes (lymphocytes, monocytes, neutrophils, eosino- 
However, until the instant embodied disclosure, it was 	 phils, and basophils) has been demonstrated with hypotonic 
necessary to dilute cell samples for cell sensors and actuators 5 dilution and fresh Acridine orange-stained leukocyte 
for many reasons. One reason dilution has been necessary is 	 samples. Adams and Kamentsky, Acta Cytol. 15, 289 (1971); 
in order to prevent the coincidence effect in which multiple 	 Adams and Kamentsky, Acta Cytol. 18, 389-391 (1974); 
cells appear in the detection zone simultaneously. In human 	 Steinkam et al., Acta Cytol. 17, 113-17 (1973). 
blood, the ratio of erythrocytes, or red blood cells, to leuko- 	 Other dyes can be utilized with certain embodiments 
cytes is on the order of about a thousand to one, a dilution io described in the instant disclosure, such as ethidium bromide, 
factor of from about one hundred to several tens of thousands 	 three-dye combinations (ethidium bromide, brilliant sulfafla- 
is typically required to avoid erythrocyte interference for 	 vine, and stilbene disulfonic acid derivative); oxazine dyes, 
electrical impedance or light scattering detection. Further- 	 basic orange 21, and a polymethine dye. Shapiro, et al., J. 
more, for counting leukocytes in samples where leukocytes 	 Histochem. Cytochem. 24, 396-411 (1976); Shapiro, et al., J. 
are specifically fluorescently labeled, a dilution of at least ten 15 Histochem. Cytochem. 25, 836-844 (1977); U.S. Pat. No. 
times is usually required. Sheenan and Storey, J. Pathol. 	 4,376,820; U.S. Pat. No. 4,882,284; Tibbe, et al., Nat. Bio- 
Bacteriol. 59; 336 (1947); Kass, J. Clin. Pathol. 76; 810-12 	 technol. 17, 1210-1213 (1999); U.S. Pat. No. 4,400,370; 
(1981); Weigl et al., Biomed. Microdeu 3; 267-274 (2001); 	 Kass, J. Histochem. Cytochem. 36, 711-715 (1988). 
Dilution is also often required in order to avoid clogging 	 Apparatus 
sample chambers, and also in order to remove erythrocytes 20 	 One embodiment of the instant disclosure relates to a 
that are lysed prior to running the sample, particularly for 	 device or apparatus for cell counting and/or differentiating. In 
electrical impedance or light scattering detection. Some of 	 particular embodiments, the device or apparatus comprises a 
these protocols also require an additional fixation buffer. 	 substrate formed from a material, such as silicon, glass, plas- 
Dyes 	 tic, metal, or other material. One particular embodiment of 
In the present disclosure, a dye, such as Acridine orange 25 the instant disclosure was fabricated using soft lithography. 
(3,6-dimethylamineoacridine, FIG. 1), can be used to differ- 	 Quake, Science 290, 1536-40 (2000). Other photolitho- 
entiate a target, such as cells, organelles, granules, nuclei, 	 graphic or etching techniques could also be used, according to 
molecules (including double or single stranded nucleic acids, 	 specific embodiments. 
such as DNA, or RNA, chromosomes, and also including 	 One embodiment of the device was microfabricated using 
synthetic forms). In one particular embodiment, leukocytes 30 two parts of PDMS (polydimethylsiloxane) (Sylgard 184, 
may be detected, counted, or sorted without need for lysing 	 Dow Corning, MI, USA) mixed vigorously in 10:1 ratio. 
erythrocytes or fixing the cell sample. Certain dyes, such as 	 After degassing in vacuum for about 30 minutes, the mixture 
Acridine orange, are also desirable due to the fast diffusion 	 was poured onto DRIE-etched silicon mold, that had been 
into cells, easy commercial availability, and excitation and 	 pretreated with HMDS (hexamethyldisilazane) for easy sepa- 
emission wavelength compatibility with common light 35 ration after baking. The molds were baked at 80° C. for 30 
sources (i.e. argon laser and other broad spectrum light 	 minutes. The hardened PDMS was separated from the silicon 
sources in visible range) and optical filters. Kosenow, Acta 	 mold, and PDMS sheet was cut into pieces and fluidic access 
Haematol. 7, 217 (1952); Schiffer, Blood, 19, 200 (1962); 	 holes were punctured on each piece with a Luer stub adapter 
Jackson, Blood, 17, 643 (196 1); Hallermann et al., PerhDeut- 	 (Becton Dickinson, N.7., USA). Each PDMS piece was care- 
sch Gies Inn Med. 70, 217 (1964). 	 40 fully placed on a cleaned glass slide and baked overnight at 
Acridine orange is a pH-sensitive fluorescent cationic dye 	 80° C. In some cases, oxygen plasma treatment (300 m Torr, 
that binds to double-stranded DNA by electrostatic attraction 	 25 W, 30 s) was used for PDMS and glass slides in order to 
and intercalation of the Acridine orange between base pairs. 	 improve adhesion between them, particularly with devices 
Upon binding, the excitation maximum becomes 502 nm and 	 that were intended to be reused. Bhattacharya et al., J. Micro- 
the emission maximum becomes 525 nm (green). Acridine 45 electromechan. Syst. 14, 590-97 (2005). 
orange also binds to RNA and single-stranded DNA, with a 	 In one particular embodiment, the channel structure was 
shifted excitation maximum of 460 nm and an emission maxi- 	 molded on a 1 cmxI cm PDMS block, with the thickness of 
mum of 650 nm (red). Adams and Kamentsky, Acta Cytol. 15, 	 the PDMS block at less than 3 mm. In one particular embodi- 
289 (1971); Adams and Kamentsky Acta Cytol. 18, 389-91 	 ment the channel depth was 16 µm in order to accommodate 
(1974); Steinkam et al., Acta Cytol. 17,113-17 (1973). Acri-  50 large leukocyte sizes. 
dine orange is also desirable in that it is hydrophobic in 	 One exemplary embodiment of the device is shown in FIG. 
neutral pH, and can easily diffuse through the cell membrane 	 2. For this particular embodiment, a first fluid flow inlet 200 
and cell nuclear membrane to bind to RNA and DNA. In 	 allows for deposition of, for example sheath flow fluid, and is 
living cells, Acridine orange is protonated in the acidic envi- 	 in fluid communication with a bifurcated channel with a first 
ronment of lysosomes, which makes it cationic and prevents 55 channel arm 260 and a second channel arm 270 that both 
the dye from leaking out of lysosome membranes. Moriyama 	 converge at a junction of a reservoir 290 and the detection 
et al., J. Biochem. 92; 1333-36 (1982). WhenAcridine orange 	 zone 240. In this particular embodiment, the apparatus further 
is used for leukocyte analysis, the cell nucleus is stained green 	 comprises a second fluid flow inlet 210 that allows for depo- 
with slightly mixed red, a result of double-stranded DNA and 	 sition of, for example, a sample fluid, such as blood, that is in 
single-stranded RNA, while the cell cytoplasm is stained red 60 fluid communication with a filter array structure 230, byway 
due to the RNA and lysosomes. Thus, leukocyte counting can 	 of a branched sample flow zone channel 220 and a fluid flow 
be achieved easily by using the strong signal from the green 	 outlet 250. In this particular exemplary embodiment, 2-D 
fluorescent channel. Leukocyte differentiation can be 	 hydrodynamic focusing was adopted to control the particle 
achieved by analyzing the signal from the red fluorescence 	 position of the cell sample in the detection zone 240. Accord- 
channel. 	 65 ing to the embodiment shown in FIG. 2, the ratio of cross- 
For fresh-stained leukocytes, a 3-part differential (lympho- 	 sectional area of sheath flow to core sample flow was 10:1, 
cytes, monocytes, and granulocytes) can be achieved by 	 and the channel width of the detection zone 240 was 50 µm, 
US 9,234,884 B2 
7 
with the width of the focused sample flow preferably 5 µm or 
less. In particular embodiments, the channels comprise a 
physical feature, such as a depression or a protrusion. 
One other exemplary embodiment of the device is shown in 
FIG. 13A. For this particular embodiment, the fluid flow inlet 
1340 allows for deposition of a sample fluid, such as a bio-
logical sample, or other fluid sample containing a target. In 
one particular embodiment, the biological sample includes a 
cell sample, such as blood. In this exemplary embodiment, 
the fluid inlet is in fluid communication with a first channel 
1330 which contains a restrictive access 1320 that is juxta-
posed to a second channel 1310 which comprises the detec-
tion zone which is also in fluid communication with the fluid 
flow outlet 1300. In certain embodiments, the height of the 
first and/or second channels is approximately 5 µm, approxi-
mately 8 µm, approximately 10 µm, approximately 12 µm, 
approximately 15 µm, approximately 20 µm, approximately 
25 µm, approximately 30 µm, approximately 35 µm, approxi-
mately 40 µm, or any value therebetween. In certain embodi-
ments, the width of the second channel is approximately 5 
µm, 10 µm, approximately 15 µm, approximately 20 µm, 
approximately 25 µm, approximately 30 µm, approximately 
35 µm, approximately 40 µm, approximately 45 µm, approxi-
mately 50 µm, or any value therebetween. In the exemplary 
embodiment shown in FIG. 13A, the second channel width 
was approximately 20 µm in size. 
One other exemplary embodiment of the device is shown in 
FIG. 13B. For this particular embodiment, the fluid flow inlet 
1440 allows for deposition of a sample fluid, such as a bio-
logical sample, or other fluid sample containing a target. In 
one particular embodiment, the biological sample includes a 
cell sample, such as blood. In this exemplary embodiment, 
the fluid inlet is in fluid communication with a first channel 
1430 which contains a restrictive access 1420 that is juxta-
posed to a second channel 1410 which comprises the detec-
tion zone which is also in fluid communication with the fluid 
flow outlet 1400. In certain embodiments, the height of the 
first and/or second channels is approximately 5 µm, approxi-
mately 8 µm, approximately 10 µm, approximately 12 µm, 
approximately 15 µm, approximately 20 µm, approximately 
25 µm, approximately 30 µm, approximately 35 µm, approxi-
mately 40 µm, or any value therebetween. In certain embodi-
ments, the width of the second channel is approximately 5 
µm, 10 µm, approximately 15 µm, approximately 20 µm, 
approximately 25 µm, approximately 30 µm, approximately 
35 µm, approximately 40 µm, approximately 45 µm, approxi-
mately 50 µm, or any value therebetween. In the exemplary 
embodiment shown in FIG. 1313, the second channel width 
was approximately 30 µm in size. 
Certain embodiments of the device use a focused laser 
source for illumination, since cell focusing in the detection 
zone 240 is highly desirable. However, other embodiments 
included in the present disclosure use a more uniform dif-
fused light source and a slit aperture. Such embodiments 
utilize straight channel geometry without cell focusing. In 
one embodiment, the channel length of the detection zone 240 
is 1000 µm. A filter structure 230 upstream of the sample flow 
zone 220 may also be included in certain embodiments, 
which filtered out contaminants, including erythryocyte rou-
leaux, and other large particle aggregates to prevent clogging 
in the detection zone 240. In certain embodiments, the size of 
the rectangular pillar structure components of the filter struc-
ture 230 was 200 µmx40 µm. The spacing between the pillars 
in each of the three rows was 40 µm, 30 µm, and 20 µm 
respectively, which allows for even the largest leukocytes to 
pass through the filter region 230. 
8 
System 
The optical system was set up on an optical bench as shown 
in FIG. 3 (transmitted laser-induced fluorescent detection 
system or LIF). In one particular embodiment, the system 
5 setup comprises an excitation or laser source 300, a lens 
assembly 340, the microfluidic apparatus 350, an optional 
additional lens assembly 360, a filter assembly 320, 330, and 
an image capture device 390, 395. In certain embodiments, 
one or more emission filters comprise the filter assemblies 
io 320, 330. In certain embodiments, the image capture device 
395 comprises a charge coupled device (CCD) camera, a 
complementary metal-oxide-semiconductor (CMOS) device, 
or a photomultiplier tube (PMT) device. In particular embodi-
ments, the image capture device 395 may be coupled to com- 
15 municate with a display unit or computing device 396, such as 
a personal computer. One of skill in the art would recognize 
that multiple and various computer software programs are 
available that allow for integration, compilation, analysis, 
reconfiguration, and other manipulation of data received from 
20 the system, particularly by way of the computing device 396. 
In one particular exemplary embodiment, an argon laser 
(National Laser NLC2I OBL, 488 nm, and 15-30 mW adjust-
able, Salt Lake City, Utah, USA) is used as the excitation 
source. An aperture 310 of 50 µm diameter is put in front of 
25 the laser output to facilitate the alignment process and lower 
the illumination intensity. In certain embodiments, an 
optional laser-line bandpass filter (bandwith equal to about 
1.9 nm with a central wavelength of 488 mu) is used to further 
purify the laser source. In certain other embodiments, an 
30 optional neutral density filter (NDF) is used to attenuate laser 
excitation. Alternatively, the pinhole and NDF are replaced 
by two linear glass polarizers (Edmond Optics TECH SPEC, 
Barrington, N.J., USA) so that the illumination level on the 
device can be easily adjusted. 
35 	 In one particular embodiment, a long-working-distance 
microscope objective (USMCO M Plan Apo, 10x, 0.28 NA, 
Dayton, Nev., USA) is used as a condenser lens 340. Another 
long-working-distance microscope objective (Bausch & 
Lomb, 50x, 0.45 NA, Rochester, N.Y., USA) is used as an 
40 objective lens 360. In the same embodiment, three emission 
filters 320 are used in one particular test: 488 nm long pass 
filter (Chroma H1500 LP, transition width <4.9 mu, edge 
steepness=2.5 mu, Rockingham, Vt., USA), a greenbandpass 
filter with central wavelength 525 nm and a bandwidth 50 nm 
45 (Chroma D52550 m), and a red bandpass filter with central 
wavelength 650 nm and bandwidth 50 nm (Chroma D650 
50 m). A broadband non-polarizing hybrid cube beamsplitter 
370 (Newport 05BC17MB.1, 400-700 mu, R/T=45%/45%, 
Irvine, Calif., USA) is used to direct light to the photodiode 
5o detector 380 and CCD camera simultaneously. 
The signal is electrically amplified and detected either with 
a silicon photodiode receiver module 390 (Electro-Optical 
Systems, UVS-025-H, Phoenixville, Pa., USA) or a photon 
multiplier tube (PMT, Hamamatsu H5784-20, Japan). The 
55 voltage signal is sent to a deep memory oscilloscope (HP 
54645A, Palo Alto, Calif., USA). When the buffer in the 
oscilloscope is full, the data can be loaded to a computer and 
analyzed with a Matlab peak-detection program. Video may 
be taken with an analog CCD camera (Hitachi KP-D20B, 
60 Japan) at 30 frames per second and then converted to digital 
format and stored in a computer 396. Other imaging capture 
devices 395, such as CMOS, PMT, or still other devices may 
also be used with particular embodiments described herein. In 
certain exemplary test runs, the system set up utilizing a 
65 photodiode detector and PMT are more sensitive than the 
CCD camera and have a faster time response. During one 
exemplary test run, the optical system was first roughly 
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aligned on a dummy device with the aid of images from CCD 
camera. A 10 M diameter illumination spot on the detection 
zone is easily achieved with proper alignment. 
As shown in FIG. 12A and FIG. 12B, the instant apparatus 
may be incorporated into a hand-held unit comprising a laser 5 
source (such as a laser emitting diode or LED 120), at least 
one lens 190, at least one filter assembly with optional beam-
splitter 195, a microfluidic apparatus as described herein on a 
microchip or other substrate 185, an input/output port 130, at 
least one image capture device 100, 110, which may be a io 
photomultiplier tube. In certain embodiments, the hand-held 
unit may be assembled and enclosed by an outer casing or 
casings 150, 180, and rivets or bolts 140, 160. 
Cell Detection 
One aspect of the instant disclosure relates to methods of 15 
counting and/or differentiating cells, particularly leukocytes, 
from undiluted cell samples, such as human or other animal 
blood, by utilizing microfabricated devices. In one exemplary 
embodiment, cell detection was conducted utilizing Acridine 
orange and fresh whole human blood. 20 
In one exemplary embodiment, fresh human blood was 
obtained from healthy donors and used within 3 days of 
collection. EDTA was added to the blood samples in order to 
prevent coagulation. For Acridine orange staining, the stock 
solution was added to obtain a final dye concentration of 10 25 
µg/mL in Ficoll-Paque Plus. Ficoll-Paque Plus was also used 
as the sheath flow solution. Fluorescent polystyrene beads (5 
µm green fluorescent beads) were purchased from Duke Sci-
entific Corporations, Fremont, Calif., USA. Cell nucleus 
stain Acridine orange was obtained from Molecular Probes, 30 
Eugene, Oreg., USA, and dissolved in water to achieve a 10 
mg/mL stock solution. Blood diluent Ficoll-Paque Plus was 
purchased fromAmersham Biosciences, Sweden. Phosphate 
buffered saline (10xPBS) was obtained fromAmbion (9625), 
Austin, Tex., USA. 35 
Staining results were observed under a fluorescent micro-
scope (Nikon E800, Japan) with a triple band fitter block 
DAPI-FITC-TRITC, which has excitation filter wavelengths 
of 385-400 mu, 475-490 run, and 545-565 run, and emission 
filter wavelengths of 450-465 nun, 505-535 nm and 580-620 40 
run. Images were taken with a cooled CCD camera (RT-KE 
color 3-shot, Diagnostic Instruments, Sterling Heights, 
Mich., USA). Rough count of leukocytes was made with a 
hemactyometer (Hausser Scientific, Horsham, Pa., USA). 
Whennecessary, blood or fluorescent beads were dilutedwith 45 
Ficoll-Paque Plus (specific gravity 1.077 g/mL) to match the 
specific gravity of the solvent to leukocytes. All fluids were 
pumpedinto the devices using syringepumps (HarvardAppa-
ratus Pico Plus, Holliston, Mass., USA). 
In this particular embodiment, an analog CCD camera was 50 
used for video recording at a matched camera frame rate of 3 
nL/min sample flow rate and 30 nL/min sheath flow rate. For 
photodiode detection, a 0.1 µL/minute sample flow rate and a 
1 µL/minute sheath flow rate were used. A 1 µL/minute 
sample flow and a 10 µL/minute sheath flow were used with 55 
the photon multiplier tube instrument. 
In order to achieve a high signal-to-noise ratio, the maxi-
mal concentration for cell staining was established using 
routine methods in the art. Adams and Kamentsky, Acta 
Cytol. 15; 289 (1971). As shown in FIG. 4, whole blood 60 
samples were analyzed with different Acridine orange con-
centrations. The optimal concentration for leukocyte staining 
was determined to be approximately in the range of 1 µg/mL. 
In the particular exemplary embodiment utilized in FIG. 4, 
the distance between the coverslip and the grid surface was 65 
approximately 100 µm. As can be seen in FIG. 4A, an abun-
dance of erythrocytes were present under the field of view, yet  
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these cells did not interfere with the fluorescent signal from 
the leukocytes, as shown in FIG. 413-F. 
As can be seen in FIG. 5, the exemplary embodiment 
utilized in cell detection did not experience any significant 
photobleaching. The signal was fitted as a first-order expo-
nential decay with time constant of 6.4+/-0.7 seconds. Two 
more tests confirmed that the photobleaching time constant 
for one particular embodiment was between 1 second and 10 
seconds. The photobleaching time constant for one particular 
embodiment was characterized by filling the device with 
Acridine orange-stained whole blood. The channel was 
scanned by the laser spot and the illumination was set to be the 
same as that used in testing. The entire process was recorded 
with a CCD camera. Whenever a fluorescing leukocyte was 
observed with fluorescent emission clearly distinct from the 
background, we stopped moving the laser spot and waited 
until the leukocyte was photobleached to background level. 
The images were extracted from the video, converted to 8-bit 
gray scale images, and analyzed with a Matlab program. The 
data was fitted to a single time-constant exponential decay. 
Additionally, green fluorescent beads were tested at a con-
centration of about 2x10 3/µL, as observed by CCD camera, 
and shown in FIG. 6. Sample flow rate was set at about 3 
nL/min, and sheath flow was about 30 nL/min. In one exem-
plary test run, a hydrodynamic focused laser beam, as shown 
in FIG. 6A, created an enlarged light circle as shown in FIG. 
6B. Only a single bead normally appeared in each image. 
With diffused laser illumination, as shown in FIG. 6C, the 
trace of the bead could be identified, as shown in FIG. 6D. 
Hydrodynamic focusing limits the cross-sectional area of the 
detection zone without shrinking the channel diameter, thus 
the signal-to-noise ratio may be improved without increasing 
the risk of clogging the channel. Also, the reduction of the 
cross-section of the core flow reduces the coincidence effect. 
Finally, enclosing the core sample flow with sheath flow 
minimizes fluorescent dye absorption in the device walls, 
thus reducing background noise. As indicated in FIG. 7, bead 
signals from the photodiode detector could easily be identi-
fied. 
As shown in FIG. 8, using both red and green emission 
filters, images extracted from video taken by the CCD camera 
show the signal identified from a leukocyte stained withAcri-
dine orange, as well as the signal obtained from the fluores-
cent control bead. For photodiode detection, the expected 
leukocyte detection rate would average about 4-11 cells per 
second for a normal individual. 
In one exemplary embodiment, a time trace over 50 sec-
onds of an undiluted blood sample stained with Acridine 
orange using a green emission filter, and a throughput of up to 
about 1000 leukocytes per second was attained. Maxima sig-
nal intensity (peak height as in FIG. 9) from the green fluo-
rescent channel with 525 nm emission filter was studied by 
plotting its histogram, as shown in FIG. 10. As expected, the 
lower-intensity portion is likely contributed mainly by lym-
phocytes, while the higher-intensity portion is likely mainly 
from monocytes, with the center-region is likely mostly from 
granulocytes. Steinkam et al., Acta Cytol. 17; 113-117 
(1973). 
In one exemplary embodiment, a time trace over 50 sec-
onds of an undiluted blood sample stained with Acridine 
orange using a red fluorescent channel with 650 nm emission 
filter was conducted. As shown in FIG. 11, two peaks were 
identified, the lower intensity is dominated by lymphocytes 
and the higher-intensity peak is largely monocytes and granu-
locytes. The time between the start of staining the cells to 
photodiode recording was typically greater than 15 minutes. 
US 9,234,884 B2 
11 
In both exemplary studies, the maximal throughput was 
about 1000 leukocytes per second utilizing one embodiment 
of the PMT detector. By using undiluted blood, minimal 
sample volume was maintained, which increases the through-
put. Since sample throughput is proportional to volume flow 
rate, but is limited by the maximal pumping rate and response 
time of the sensing system, a 3 nL/minute core flow rate was 
used with the CCD camera detection. Under this flow rate, a 
typical leukocyte traveled through the detection zone in 
approximately 30 milliseconds, which roughly equals the 
CCD frame acquisition time. 
Flow rates for varying embodiments may be suitable for a 
range from approximately I nL/minute, approximately 2 
nL/minute, approximately 3 nL/minute, approximately 4 
nL/minute, approximately 5 nL/minute, approximately 6 
nL/minute, approximately 7 nL/minute, approximately 8 
nL/minute, approximately 9 nL/minute, approximately 10 
nL/minute, approximately 20 nL/minute, approximately 30 
nL/minute, approximately 40 nL/minute, approximately 50 
nL/minute, approximately 60 nL/minute, approximately 70 
nL/minute, approximately 80 nL/minute, approximately 90 
nL/minute, approximately 100 nL/minute, approximately 
110 nL/minute, approximately 120 nL/minute, approxi-
mately 130 nL/minute, approximately 140 nL/minute, 
approximately 150 nL/minute, or any value therebetween for 
photodiode detection. Likewise, for PMT detection, flow 
rates for varying embodiments may be suitable for a range 
from approximately 200 nL/minute, approximately 300 
nL/minute, approximately 400 nL/minute, approximately 
500 nL/minute, approximately 600 nL/minute, approxi-
mately 700 nL/minute, approximately 800 nL/minute, 
approximately 900 nL/minute, approximately I µL/minute, 
approximately 2 µL/minute, approximately 3 µL/minute, 
approximately 4 µL/minute, approximately 5 µL/minute, or 
any value therebetween. 
In one exemplary embodiment, the time response of the 
photodiode receiver module under low sensitivity setting was 
0.16 milliseconds, and 0.6 milliseconds under high sensitiv-
ity, while the time response of the PMT detector in one 
exemplary run was about 16 microseconds. 
Furthermore, by decreasing the cross-sectional area, the 
linear flow velocity of the core flow is increased, which 
requires faster sensing, and reduces the coincidence effect by 
increasing the average distance between cells in the detection 
zone. 
Thus, by utilizing particular embodiments disclosed herein 
relating to a microfluidic device, leukocyte sensing, counting, 
and sorting can be achieved one-by-one in a micro flow 
cytometer system. Furthermore, dense cell suspensions, such 
as whole, undiluted blood may be utilized in certain embodi-
ments described herein, which provides for reduced sample 
and waste volume, reduced processing time, and completely 
eliminates on-chip mixing and buffer storage. In particular 
aspects, leukocytes can be sensed one-by-one in a micro flow 
cytometer system. 
As described herein, certain embodiments of the device 
can be implemented in various sizes and conformations, 
including but not limited to a bench-top device, a handheld 
device (such as is shown in FIG. 12), an implantable device, 
a nanotechnology device, or other size or conformation. In the 
smaller exemplary conformations, high-illumination LED is 
used for excitation and a minipump is used to manipulate the 
sample in suction mode, while fluorescent signals from green 
and red channels can be detected simultaneously. 
INCORPORATION BY REFERENCE 
All of the above U.S. patents, U.S. patent application pub-
lications, U.S. patent applications, foreign patents, foreign 
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this specification and/or listed in the Application Data Sheet, 
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5 	 The invention claimed is: 
1. A method for analyzing cells, the method comprising: 
a) introducing a blood sample comprising fluorescently 
labeled cells and fluorescently labeled control beads to 
an inlet of a first microfluidic channel that gradually 
10 narrows, wherein the fluorescently labeled cells are 
labeled with a fluorophore different than a fluorophore 
label of the control beads; 
b) flowing the blood sample from the inlet of the first 
microfluidic channel to an outlet of a second microflu- 
15 	 idic channel, wherein the second microfluidic channel is 
directly coupled to the first microfluidic channel; 
c) exciting the fluorophores of the fluorescently labeled 
cells and of the fluorescently labeled control beads using 
an excitation source; 
20 	 d) detecting fluorescence of the fluorescently labeled cells 
and fluorescence of the fluorescently labeled control 
beads as they pass through a detection zone in the second 
microfluidic channel, wherein the detection is per-
formed on individual cells; 
25 	 e) measuring the fluorescence of the fluorescently labeled 
cells and of the fluorescently labeled beads using a light 
sensor; and 
f) using the measured fluorescence to thereby provide a 
result concerning the blood sample. 
30 	 2. The method of claim 1, wherein the cells are leukocytes. 
3. The method of claim 1, wherein the blood sample is a 
whole blood sample. 
4. The method of claim 1, wherein the blood sample is 
modified blood sample. 
35 	 5. The method of claim 1, wherein the second microfluidic 
channel has fixed dimensions. 
6. The method of claim 1, wherein the first channel and the 
second channel are obstacle-free. 
7. The method of claim 5, wherein the fixed dimensions are 
40 of approximately 40 microns by approximately 50 microns. 
8. The method of claim 1, wherein the flowing of the blood 
sample from the inlet of the first microfluidic channel to the 
outlet of the second microfluidic channel increases a core 
flow rate of the blood sample to form an increased flow rate. 
45 9. The method of claim 1, wherein the method further 
comprises identifying the fluorescently labeled cells. 
10. The method of claim 1, wherein the method further 
comprises sorting the fluorescently labeled cells. 
11. The method of claim 1, wherein the method further 
50 comprises counting the fluorescently labeled cells. 
12. The method of claim 1, further comprising recording a 
measurement on a recording unit. 
13. The method of claim 1, further comprising recording 
the result on a recording unit. 
55 14. The method of claim 1, wherein the method can detect 
leukocytes at arate of up to about 1000 leukocytes per second. 
15. The method of claim 1, wherein the excitation source is 
a laser or a LED. 
16. The method of claim 1, wherein the excitation source 
60 comprises a lens assembly. 
17. The method of claim 1, further comprising manipulat-
ing the fluorescence measurement using a computer software 
inscribed on a computing device. 
18. The method of claim 17, further comprising displaying 
65 a result of the manipulation on a display unit. 
19. The method of claim 1, wherein the fluorescently 
labeled beads are polymeric beads. 
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20. The method of claim 1, wherein the fluorescently 
labeled beads are polystyrene beads. 
21. The method of claim 1, wherein detecting a level of 
fluorescence comprises using an image capture device. 
22. The method of claim 1, wherein flowing the blood s 
sample comprises pumping the blood sample through a 
microfluidic device. 
23. The method of claim 1, wherein the blood sample does 
not comprise a sheath fluid. 
24. The method of claim 1, wherein the blood sample is an io 
undiluted blood sample. 
25. The method of claim 1, wherein the light sensor is a 
photomultiplier. 
